Management of Juvenile Idiopathic Arthritis-associated Uveitis during the COVID-19 Pandemic in a Pediatric Referral Center in Lombardy.
Management of Juvenile Idiopathic Arthritis-associated Uveitis during the COVID-19 Pandemic in a Pediatric Referral Center in Lombardy.
Ocul Immunol Inflamm. 2020 Sep 25;:1-3
Authors: Miserocchi E, Giuffrè C, Modorati GM, Cimaz R
Abstract
Italy was the first European country to be affected by the SARS-CoV-2 pandemic. In this scenario, we had to face a new clinical approach in our Pediatric Rheumatology Unit for the management of patients affected by juvenile idiopathic arthritis (JIA)-associated uveitis. During the lockdown (phase 1), the weekly outpatient clinic was discontinued and telephone consultations were set up. A toll-free telephone number was instituted for emergencies. None of our children with JIA-associated uveitis was advised to stop the ongoing immunosuppressant systemic therapy. We had no cases of COVID-19 infection and uveitis activity was under control in all but two out of 125 patients, which was comparable with the pre-COVID-19 situation. During phase 2 of the pandemic, hospital and ambulatory rearrangements were made to minimize the risk of SARS-CoV-2 infection. Overall, during the first 4 weeks of phase 2, we did not notice an increased number of patients with uveitis activity.
PMID: 32976038 [PubMed - as supplied by publisher]
Source: Ocular Immunology and Inflammation - Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research
More News: Allergy & Immunology | Arthritis | Children | COVID-19 | Emergency Medicine | Hospitals | Italy Health | Pandemics | Pediatrics | Rheumatology | SARS